LinkedIn Image

The Dawn of Immunotherapy in Gastric and Colorectal Cancers

Meeting Overview

We are pleased to invite you to our satellite symposium, The Dawn of Immunotherapy in Gastric and Colorectal Cancers, to be held on January 20, 2017, in San Francisco, California.


7.15 PM Registration and dinner
7.30 PM Welcome and introduction
Brain Teasers
Alan Venook, MD
7.35 PM The immunotherapy entrée into gastrointestinal cancers
A. Craig Lockhart, MD, MHS
Q & A
8.00 PM How do you measure success with immunotherapy?
Alan Venook, MD
Q & A
8.25 PM Drilling down on immunotherapy in colorectal cancer: What we know and what we need to know
Richard M Goldberg, MD
Q & A
8.50 PM Immunotherapy in gastric cancer: Are there markers for success?
Bert O’Neil, MD
Q & A
9.15 PM Faculty panel discussion
9.25 PM Brain Teasers revisited
prIME Points™
Alan Venook, MD
9.30 PM Adjourn


  • Alan Venook, MDUniversity of California, San Francisco
    San Francisco, California, United States
  • Richard M. Goldberg, MDWest Virginia University
    Morgantown, West Virginia, United States
  • A. Craig Lockhart, MD, MHSWashington University
    Siteman Cancer Center
    St Louis, Missouri, United States
  • Bert O’Neil, MDIndiana University
    Indianapolis, Indiana, United States

Target Audience

This educational activity is specifically designed to meet the needs of medical oncologists, radiation oncologists, and other healthcare professionals involved in the treatment of patients with gastrointestinal cancers.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Describe the molecular basis for immunotherapy in cancers and the evidence supporting the theory that gastric and colorectal cancers are immunogenic
  • Identify potential biomarkers of response to immunotherapy in gastric and colorectal cancers, with a focus on immune checkpoint inhibitors
  • Assess new and emerging data supporting the efficacy of immunotherapy in colorectal cancer, the rationale for combining it with other agents, and important ongoing trials
  • Evaluate the evidence for the use of immunotherapy in gastric cancer alone or in combination with other agents, and describe late-phase, ongoing clinical trials
  • Contrast the unique aspects of monitoring response to immunotherapy and the unique potential treatment-emergent adverse events from immunotherapy with chemotherapy or targeted agents
Register Now

There is no fee for this activity and preregistration is not required; however, space is limited. Dinner will be served.

Date and Location

Friday, January 20, 2017
7.15 PM – 9.30 PM

Yerba Buena Ballroom – Salon 7
San Francisco Marriott Marquis
780 Mission Street
San Francisco, California


This activity is provided by prIME Oncology.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.


prIME Oncology designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This educational activity is supported by a grant from Merck and Co, Inc.

Sunshine Act and EFPIA Disclosure Code

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.